Managing pulmonary embolism in primary care feasible for some patients
Jan 25, 2022
About 21 percent of adults diagnosed with acute PE in primary care sent home; few experienced adverse events within 30 days
Strategies compared for ruling out pulmonary embolism
Dec 13, 2021
Diagnostic strategies with pretest probability-dependent D-dimer thresholds have highest efficiency, highest predicted failure rate
FDA approves XARELTO Starter Pack for DVT
Oct 21, 2014
FDA has approved the XARELTO Starter Pack™ for deep vein thrombosis or pulmonary embolism. The medication is use to reduce the risk of stroke or blood clots in those with atrial fibrillation not caused...
Xarelto may be alternative for cancer patients with VTE
Sep 30, 2014
Patients with cancer who have had venous thromboembolism may have lower risk of bleeding with XARELTO® (rivaroxaban) , a study in Lancet Haematology suggests
FDA approves new anti-clotting drug for use after hip and knee replacements
Jul 06, 2011
The Food and Drug Administration has approved a new oral anticoagulant that helps prevent deep vein thrombosis in people recovering from knee or hip replacements.